Clinical-stage biotech developing sonelokimab, an IL-17 Nanobody, for hidradenitis suppurativa and psoriatic arthritis.
Clinical-stage biotech developing sonelokimab, an IL-17 Nanobody, for hidradenitis suppurativa and psoriatic arthritis.
Pre-revenue: it sells nothing and funds development from cash raised since its listing through a merger with a blank-check company. Its single drug, sonelokimab, was licensed in from Merck KGaA, so approval and sales would trigger milestone and royalty payments to that partner.
Moat: narrow (IP / patents). Nanobody format may offer better tissue penetration than standard IL-17 antibodies, if confirmed in trials.
Headquarters: Zug, Switzerland · Founded: 2021 · Employees: 130
Size MoonLake Immunotherapeutics (MLTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $918M, the 2283rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.79 on 18 Nov 2026.
Performance Over six months the shares fell 36.7%, against -20.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$3.40M | -$2.62M | -$1.38M | -$13,158 | -$12,358 |
| EBITDA | -$273M | -$242M | -$142M | -$54.1M | -$65.0M |
| Net income | -$273M | -$227M | -$119M | -$36.0M | -$50.0M |
| Free cash flow | -$244M | -$196M | -$117M | -$43.1M | -$55.9M |
| Capital expenditure | $0 | $35,000 | $519,520 | $284,634 | $16,009 |
| Total debt | $102M | $75.7M | $2.83M | $3.70M | $282,580 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics MLTX | $918M | -37% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MLTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.5% | -10.0% | 2nd highest of 21 |
| 6-month return | -36.7% | -20.9% | 6th lowest of 20 |
| Distance from 52-week high | -53.7% | -46.6% | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |